Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date19 May 2020 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date27 May 2019 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date01 Jan 1996 |
/ Not yet recruitingPhase 4IIT A single-center, prospective, self-controlled study on the efficacy and safety of Suoyang Gujing Pills in the treatment of male premature ejaculation (kidney deficiency syndrome)
/ Not yet recruitingPhase 4IIT A prospective cohort study on the prevention and treatment of children's bronchial asthma attack induced by acute upper respiratory tract infection with Qingfei Oral liquid based on realistic medical environment and Chinese Children's Asthma Action Plan
/ Not yet recruitingPhase 4IIT Clinical efficacy and effect mechanism of Morinda officinalis oligosaccharide capsules in the treatment of vascular depression based on the brain-gut axis
100 Clinical Results associated with Beijing Tongrentang Co. Ltd. Tongrentang Pharmaceutical Factor
0 Patents (Medical) associated with Beijing Tongrentang Co. Ltd. Tongrentang Pharmaceutical Factor
100 Deals associated with Beijing Tongrentang Co. Ltd. Tongrentang Pharmaceutical Factor
100 Translational Medicine associated with Beijing Tongrentang Co. Ltd. Tongrentang Pharmaceutical Factor